Magic mushroom compound tested for tough depression and addiction
NCT ID NCT07499583
First seen Apr 01, 2026 · Last updated Jun 22, 2026 · Updated 21 times
Summary
This study tests whether a single dose of psilocybin (the active ingredient in magic mushrooms) combined with psychotherapy is safe and can reduce depression and substance use in veterans and first responders who haven't responded to standard treatments. Fifty participants will receive one of three doses (5mg, 10mg, or 25mg) and complete therapy sessions before and after. The trial also looks at brain changes and side effects over 14 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUBSTANCE USE DISORDERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Goodman Hall, Dept of Psychiatry, Indiana University
Indianapolis, Indiana, 46202-3082, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
The Stark Neuroscience Building (Goodman Hall)
Indianapolis, Indiana, 46202, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
psilocybin
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat depression and substance use problems.
What could go wrong
This is an early-phase trial with only 50 participants, so results may not apply to everyone. Psilocybin can cause temporary anxiety or confusion during the dosing session.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.